Upgrade to SI Premium - Free Trial

Biogen (BIIB) Weakness Is Buying Opportunity - Goldman Sachs

October 24, 2017 2:35 PM
Goldman Sachs maintains Conviction Buy on Biogen (NASDAQ: BIIB) price target of $376.00.Analyst Terrance Flynn believes investors should buy ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments

Next Articles